Orgenesis Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
80
- Stock Symbol
-
ORGS
- Investments
-
16
- Share Price
-
$0.26
- (As of Thursday Closing)
Orgenesis General Information
Description
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
Contact Information
Website
www.orgenesis.comCorporate Office
- 20271 Goldenrod Lane
- Germantown, MD 20876
- United States
Corporate Office
- 20271 Goldenrod Lane
- Germantown, MD 20876
- United States
Orgenesis Timeline
Orgenesis Stock Performance
As of 19-Nov-2026, Orgenesis’s stock price is $0.26. Its current market cap is $2.6M with 9.8M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.26 | $0.02 | $2.6M | 9.8M | 1.55K |
Orgenesis Financials Summary
As of 31-Dec-2024, Orgenesis has a trailing 12-month revenue of $1.03M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 26,831 | 26,831 | 37,655 | 75,536 |
| Revenue | 1,035 | 1,035 | 530 | 36,025 |
| EBITDA | (43,091) | (43,091) | (60,718) | (8,158) |
| Net Income | (48,165) | (48,165) | (55,361) | (14,889) |
| Total Assets | 1,351 | 1,351 | 14,552 | 90,928 |
| Total Debt | 18,259 | 18,259 | 22,621 | 20,272 |
Orgenesis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Orgenesis Comparisons
Industry
Financing
Details
Orgenesis Competitors (18)
One of Orgenesis’s 18 competitors is Histogen, a Formerly VC-backed company based in San Ramon, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Histogen | Formerly VC-backed | San Ramon, CA | ||||
| Sernova Biotherapeutics | Corporation | Mississauga, Canada | ||||
| Regenerative Medical Solutions | Venture Capital-Backed | Madison, WI | ||||
| Treefrog Therapeutics | Venture Capital-Backed | Pessac, France | ||||
| PeproTech | Corporate Backed or Acquired | Cranbury, NJ |
Orgenesis Patents
Orgenesis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024226832-A1 | Ribonucleases for treating viral infections | Inactive | 25-Apr-2023 | ||
| EP-4680395-A1 | Systems and methods for bio-manufacturing | Pending | 14-Mar-2023 | ||
| EP-4680395-A4 | Systems and methods for bio-manufacturing | Pending | 14-Mar-2023 | ||
| WO-2024192060-A1 | Systems and methods for bio-manufacturing | Inactive | 14-Mar-2023 | ||
| US-20240131096-A1 | Oncolytic virus combined with car t cells for anti-tumor therapy | Pending | 24-Oct-2022 | A61K35/768 |
Orgenesis Signals
Orgenesis Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Orgenesis Investments & Acquisitions (16)
Orgenesis’s most recent deal was a Merger/Acquisition with Neurocords. The deal was made on 06-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neurocords | 06-Mar-2025 | Merger/Acquisition | Drug Discovery | ||
| Innovative Longevity & Wellness Services (Harley Street Healthcare / Orgenesis) | 31-Dec-2024 | Joint Venture | Other Healthcare Services | ||
| Octomera | 31-Jan-2024 | Secondary Transaction - Private | Biotechnology | ||
| MIDA Biotech | 01-Feb-2022 | Merger/Acquisition | Biotechnology | ||
| Joint Venture (Orgenesis & Cure Therapeutics) | 09-Dec-2020 | Joint Venture | Drug Discovery |
Orgenesis ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Orgenesis Exits (3)
Orgenesis’s most recent exit was on 31-Jan-2024 from Octomera. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Octomera | 31-Jan-2024 | Completed |
|
||
| Masthercell | 29-Jun-2018 | Completed |
|
||
| Masthercell | 27-Feb-2015 | Merger/Acquisition | Completed |
Orgenesis Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Octomera | Germantown, WI | 2022 | |
| MIDA Biotech | Leiden, Netherlands | 2020 |
Orgenesis FAQs
-
When was Orgenesis founded?
Orgenesis was founded in 2008.
-
Where is Orgenesis headquartered?
Orgenesis is headquartered in Germantown, MD.
-
What is the size of Orgenesis?
Orgenesis has 80 total employees.
-
What industry is Orgenesis in?
Orgenesis’s primary industry is Drug Discovery.
-
Is Orgenesis a private or public company?
Orgenesis is a Public company.
-
What is Orgenesis’s stock symbol?
The ticker symbol for Orgenesis is ORGS.
-
What is the current stock price of Orgenesis?
As of 19-Nov-2026 the stock price of Orgenesis is $0.26.
-
What is the current market cap of Orgenesis?
The current market capitalization of Orgenesis is $2.6M.
-
What is Orgenesis’s current revenue?
The trailing twelve month revenue for Orgenesis is $1.03M.
-
Who are Orgenesis’s competitors?
Histogen, Sernova Biotherapeutics, Regenerative Medical Solutions, Treefrog Therapeutics, and PeproTech are some of the 18 competitors of Orgenesis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process